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Abstract
Introduction: Melanoma differentiation associated gene-7 (MDA-7), also known as interleukin (IL)-24, is a tumour
suppressor gene associated with differentiation, growth and apoptosis. However, the mechanisms underlying its
anti-neoplastic activity, tumour-specificity and efficacy across a spectrum of human cancers have yet to be fully
elucidated. In this study, the biological impact of MDA-7 on the behavior of breast cancer (BC) cells is evaluated.
Furthermore, mRNA expression of MDA-7 is assessed in a cohort of women with BC and correlated with
established pathological parameters and clinical outcome.
Methods: The human BC cell line MDA MB-231 was used to evaluate the in-vitro impact of recombinant human
(rh)-MDA-7 on cell growth and motility, using a growth assay, wounding assay and electric cell impedance sensing
(ECIS). Localisation of MDA-7 in mammary tissues was assessed with standard immuno-histochemical methodology.
BC tissues (n = 127) and normal tissues (n = 33) underwent RNA extraction and reverse transcription, MDA-7
transcript levels were determined using real-time quantitative PCR. Transcript levels were analyzed against tumour
size, grade, oestrogen receptor (ER) status, nodal involvement, TNM stage, Nottingham Prognostic Index (NPI) and
clinical outcome over a 10 year follow-up period.
Results: Exposure to rh-MDA-7 significantly reduced wound closure rates for human BC cells in-vitro. The ECIS
model demonstrated a significantly reduced motility and migration following rh-MDA-7 treatment (p = 0.024).
Exposure to rh-MDA-7 was only found to exert a marginal effect on growth. Immuno-histochemical staining of
human breast tissues revealed substantially greater MDA-7 positivity in normal compared to cancer cells.
Significantly lower MDA-7 transcript levels were identified in those predicted to have a poorer prognosis by the
NPI (p = 0.049) and those with node positive tumours. Significantly lower expression was also noted in tumours
from patients who died of BC compared to those who remained disease free (p = 0.035). Low levels of MDA-7
were significantly correlated with a shorter disease free survival (mean = 121.7 vs. 140.4 months, p = 0.0287) on
Kaplan-Meier survival analysis.
Conclusion: MDA-7 significantly inhibits the motility and migration of human BC cells in-vitro. MDA-7 expression is
substantially reduced in malignant breast tissue and low transcript levels are significantly associated with
unfavourable pathological parameters, including nodal positivity; and adverse clinical outcomes including poor
prognosis and shorter disease free survival. MDA-7 offers utility as a prognostic marker and potential for future
therapeutic strategies.
Introduction & Background
Melanoma differentiation associated gene-7 (MDA-7),
also known as interleukin (IL)-24, is an intriguing mem-
ber of the class II/IL-10 cytokine family [1]. This novel
tumour suppressor gene was initially identified from
human melanoma cells [2,3]. Mapped within the IL-10
family cytokine cluster to 1q32.2-q41, the gene encodes
a protein consisting of 206 amino acids, secreted in
mature form as a 35-40 kDa phosphorylated glycopro-
tein [4,5]. MDA-7 is expressed by diverse cell types,
including: B cells, Nk cells, dendritic cells, monocytes
and melanocytes. Although its physiological role is
poorly understood, forced expression of MDA-7 in can-
cer cells results in irreversible growth inhibition, reversal
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of the malignant phenotype and terminal differentiation
[6]. Further in-vitro and in-vivo studies have demon-
strated these attributes to be tumour-selective and
applicable to numerous solid malignancies. Many
human cancer derived cell lines, including: prostate,
breast, cervical, lung, fibrosarcoma, colorectal, mela-
noma, and glioblastoma, undergo apoptosis when
exposed to MDA-7 [7-12]. Interestingly, similar effects
are not apparent following transduction into their non-
malignant counterparts [13]. Specific anti-tumour activ-
ity has also been established in a range of human
tumour xenograft models and recently in several early-
phase clinical trials involving patients with advanced
solid cancers [10,11,14,15]. MDA-7 is emerging as a dif-
ferentiation, growth and apoptosis associated gene with
potential utility for the gene-based therapy of several
human cancers [4].
However, the mechanisms through which MDA-7
expression exerts its anti-neoplastic activity, tumour-
specificity and efficacy across a spectrum of human can-
cers have yet to be fully elucidated. Akin to other cyto-
kines, secreted MDA-7 operates via its cell surface
receptor complex, involving the IL-20R1/IL-20R2 or IL-
22R1/IL20R2 hetero-dimers [16,17]. Although receptor
activation is associated with the Janus activated kinase
(JAK)/signal transducers and activators of transcription
(STAT) signalling, specific tumour suppressor function
may not be entirely dependent upon these pathways
[18]. Indeed, selective anti-tumour activity is believed to
be exerted through both secretory (extra-cellular) and
non-secretory (intra-cellular) pathways [19,20]. Intra-cel-
lular activity is thought to be mediated in a cell surface
receptor-independent manner, involving endoplasmic
reticulum (ER) signalling, as evidenced by localisation
studies, interaction with resident ER chaperones and the
induction of particular genes associated with the ER
stress response [13,21-23]
In this study, the biological impact of MDA-7 on the
behavior of breast cancer (BC) cells is evaluated.
Furthermore, mRNA expression of MDA-7 is assessed
in a cohort of women with BC. Transcript levels are
compared with normal background tissues and evalu-
ated against established pathological parameters and
clinical outcome over a 10 year follow-up period.
Methods
Patients, materials and cell lines
The human BC cell line MDA MB-231 was obtained
from ATCC (American Type Cell Collection, Maryland,
USA). BC tissues (n = 127) and normal background tis-
sues (n = 31) were collected from University Hospital of
Wales and St George’s Hospital and Medical School;
institutional guidelines, including ethical approval and
informed consent, were followed. Specimens were
obtained immediately after excision during surgery and
stored at -80°C until use. A consultant pathologist
examined haematoxylin and eosin stained frozen sec-
tions to verify the presence of tumour cells in the col-
lected samples. Normal tissue was derived from the
background breast parenchyma of BC patients within
the study group. Medical notes and histology reports
were used to extract the clinico-pathological data (Table
1). A customized database was established to record the
data. Recombinant human (rh) MDA-7/IL-24 was pur-
chased from R&D System Europe. Antibodies to human
MDA-7/IL-24, anti-IL20Ra, anti-IL20Rb, and anti-IL-
22R were obtained from Santa-Cruz Biotechnologies
Inc. ROCK inhibitor was purchased from Santa-Cruz
Biotechnologies Inc., Akt inhibitor, SIS3 inhibitor, PLC-
gamma inhibitor, JNK inhibitor, JAK inhibitor, MET
inhibitor, Wortmannin and Wiskostatin were obtained
from Calbiochem, Nottingham, England, UK. Matrigel
(reconstituted basement membrane) was purchased
from Collaborative Research Products (Bedford, Massa-
chusetts, USA). Transwell plates equipped with a porous
insert (pore size 8 μm) were obtained from Becton
Table 1 Clinical and pathological data
Parameter Category Number
Node Status Node positive 54
Node negative 73
Tumour Grade 1 24
2 43
3 58
Tumour Type Ductal 98
Lobular 14
Medullary 2
Tubular 2
Mucinous 4
Non specific 7
TNM staging 1 70
2 40
3 7
4 4
NPI NPI1 68
NPI2 38
NPI3 16
Clinical Outcome Disease free 90
Alive with metastasis 7
With local recurrence 5
Died from breast cancer 16
Died of unrelated disease 9
ER status ER a negative 75
ER a positive 38
ER b negative 91
ER b positive 24
Note: missing values reflect discarded/un-interpretable values
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Dickinson Labware (Oxford, UK). DNA gel extraction
and plasmid extraction kits were purchased from Sigma.
Tissue processing, RNA extraction, cDNA synthesis
and RT-PCR
Frozen sections of tissue were cut at a thickness of 5-10
mm and kept for routine histological analysis. Additional
15-20 sections were mixed and homogenized using a
hand-held homogenizer in ice-cold RNA extraction solu-
tion. RNA from cells was extracted using an RNA extrac-
tion kit (AbGene Ltd, Surrey, England, UK). RNA
concentration was quantified using a UV spectrophot-
ometer (Wolf Laboratories, York, England, UK). Reverse
transcription was carried out using a reverse transcrip-
tion kit, cDNA was synthesised using first strand synth-
esis with an anchored oligodt primer (AbGene, Surrey,
UK). The polymerase chain reaction (PCR) was per-
formed using sets of primers (Table 2) with the following
conditions: 5 min at 95°C, 20 seconds at 94°C, 25 seconds
at 56°C, 50 seconds at 72°C for 36 cycles and finally 72°C
for 7 minutes. b-actin was amplified and used as a house
keeping control to verify the quality of cDNA. PCR pro-
ducts were separated on a 0.8% agarose gel, visualised
under UV light, photographed using a Unisave™ camera
(Wolf Laboratories, York, England, UK) and recorded
with Photoshop software.
Quantitative analysis of MDA-7
MDA-7 transcript levels within the above-prepared
cDNA was determined using real-time quantitative PCR,
based on the Amplifluor™ technology, modified from pre-
vious reports [24,25]. Pairs of PCR primers were designed
using the Beacon Designer™ software (Version 2, Palo
Alto, California, USA) and synthesized by Sigma-Aldrich,
added to the reverse primer was an additional sequence,
known as the Z sequence (5’-ACTGAACCTGACCG-
TACA-’3) which is complementary to the universal Z
probe (Intergen Inc., Oxford, England, UK). The product
expands one intron. The primers used are detailed in
Table 2. Taqman detection kit for b-actin was purchased
from Perkin-Elmer. The reaction was carried out using
the following: custom made hot-start Q-master mix
Abgene (Surrey, England, UK), 10 pmol of specific for-
ward primer, 1 pmol reverse primer with the Z sequence
(Table 2), 10 pmol of FAM- (fluorogenic reporter dye,
carboxyfluorescein) tagged probe (Intergen Inc.), and
cDNA generated from 50 ng RNA. The reaction was car-
ried out using IcyclerIQ™ (Bio-Rad, Hemel Hempstead,
England, UK) which is equipped with an optic unit that
allows real-time detection of 96 reactions, under the fol-
lowing conditions: 94°C for 12 minutes, 50 cycles of 94°C
for 15 seconds, 55°C for 40 seconds and 72°C for 20 sec-
onds. The transcript levels were generated from an inter-
nal standard that was simultaneously amplified with the
samples. The levels of gene expression were then normal-
ized against the housekeeping control, which was also
quantified in these specimens, to correct for varying
amounts of epithelial tissue between samples [26]. With
every PCR run, a negative control without a template and
a known cDNA reference sample as a positive control,
were included.
In-vitro cell growth assay
Cells were plated into 96-well plates at 2,000 cells/well,
followed by a period of incubation. Cells were fixed in
10% formaldehyde at the day of plating and daily for the
subsequent 5 days. 0.5% crystal violet (w/v) was used to
stain cells. Following washing, the stained crystal violet
was dissolved with 10% (v/v) acetic acid and the absor-
bance was determined at a wavelength of 540 nm using
an ELx800 spectrophotometer. Absorbance was used to
represent the cell number.
Electric Cell-substrate Impedance Sensing (ECIS) based
cell adhesion assay
Cell migration was determined using a wounding assay
and ECIS assays. Two models of ECIS instrument were
used: ECIS 9600 for screening and ECIS1600R for mod-
elling. In both systems, 8W10 arrays were used (Applied
Biophysics Inc, NJ, US). The array surfaces and electro-
des were pre-treated with a Cysteine solution (10 mM)
and subsequently incubated with complete medium for
an hour. The same number of BC cells was added to
each well (300,000/well). Electric changes were continu-
ously monitored for up to 24 hours. In the 9600 system,
the monitoring was at fixed 30 Hz. In the 1600R system,
two conditions were recorded: 400 Hz, 4,000 Hz, 40,000
Hz for screening the cells response to IL-24/MDA-7
and 4,000 Hz fix frequency for cell modelling.
Immuno-histochemical analysis of MDA-7 & MDA-7
receptors in cells and tissues
Frozen sections of breast tissues (normal and tumour)
were cut at a thickness of 6 μm using a cryostat. Sec-
tions were mounted on super frost plus microscope
Table 2 Forward and reverse primers
MDA-7/IL-24 F GATGTTTTCCATCAGAGACAG
MDA-7/IL-24 Zr ACTGAACCTGACCGTACACATCCAGGTCAGAAGAATGT
IL20R1 F TACAATGGACTCCACCAGAG
IL20R1 ZR ACTGAACCTGACCGTACATATTCAGCCATTTCTTTTGC
IL20R2 F GCCTGGAGAAACAGTGTACTA
IL20R2 ZR ACTGAACCTGACCGTACACAGGACCTTCAGTGAGTGAG
CK-19 F CAGGTCCTAGAGGTTACTGAC
CK-19 Zr ACTGAACCTGACCGTACACACTTTCTGCCAGTGTGTCTTC
b-actin F ATGATATCGCCGCGCTCGTC
b-actin Zr CGCTCGGTGAGGATCTTCA
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slides, air dried and then fixed in a mixture of 50%
Acetone and 50% methanol. Sections were then placed in
“Optimax” wash buffer for 5-10 minutes to rehydrate. Sec-
tions were incubated for 20 minutes in a 0.6% bovine
serum albumin (BSA) blocking solution and probed with
the primary antibody. Sections were incubated for 20 min-
utes in a 10% horse serum blocking solution and probed
with the primary antibodies (1:100 for anti-MDA-7, anti-
IL-20Ra, and 1:150 for anti-IL20Rb and anti-IL22R). Fol-
lowing extensive washings, sections were incubated for 30
minutes in the secondary biotinylated antibody (Multi-link
Swine anti-goat/mouse/rabbit immunoglobulin, Dako
Inc.). Following washings, Avidin Biotin Complex (Vector
Laboratories) was then applied to the sections followed by
further washings. Di-amino-benzidine (DAB) chromogen
(Vector Labs) was then added to the sections which were
incubated in the dark for 5 minutes. Sections were counter
stained with Gill’s Haematoxylin and dehydrated in
ascending grades of methanol before clearing in xylene
and mounting under a cover slip.
Statistical analysis
The two-sample t-test (comparison of mean copy num-
ber) was used for statistical analysis of absolute and nor-
malised gene copy number. For normality the Anderson-
Darling test was used. The transcript levels within the BC
specimens were compared to normal background tissues
and analyzed against conventional pathological para-
meters and clinical outcome over a 10 year follow-up
period. In each case the true copy number was used for
statistical analysis and hence the samples were not classi-
fied as positive or negative. The statistical analysis was
carried out using Minitab version 14.1 (Minitab Ltd. Cov-
entry, England, U.K.) using a custom written macro (Stat
2005.mtw). For purposes of the Kaplan-Meier survival
analysis, the samples were divided arbitrarily into two
groups, ‘high transcript level’ or ‘low transcript level’. The
cut-off was guided by the Nottingham Prognostic Index
(NPI) value, with which the value of the moderate prog-
nostic group was used as the dividing line at the start of
the test. Survival analysis was performed using SPSS ver-
sion 16.0 (SPSS Inc. Chicago, IL, USA). NPI = tumour
size (cm) × 0.2 + lymph node stage (1 - no nodes
affected; 2 - up to 3 nodes affected; 3 - more than 3
nodes affected) + Grade (1-3, Scarff-Bloom-Richardson).
NPI scores were classified into three groups: < 3.4 = NPI-
1, 3.4-5.4 = NPI-2, > 5.4 = NPI-3. Within tumour sam-
ples, oestrogen receptor (ER) status was classified accord-
ing to transcript copy number per 50 ng (nanograms) of
RNA: < 1 = negative, ≥1 = positive.
Results
The MDA MB 231 cell line was confirmed to express both
IL20R1 (0.008 copies/ul) and IL-20R2 (40.5 copies/ul).
In-vitro studies demonstrated that migration of BC cells
was profoundly affected by rh-MDA-7. After scratch
wounding, exposure to rh-MDA-7 significantly reduced
the wound closure rate of MDA MB-231 cells treated with
rh-MDA-7 at 20 ng/ml, when compared to controls. The
impact of rh-MDA-7/IL-24 on BC cell migration is
depicted in Figure 1. The ECIS model confirmed that
MDA MB-231 cells treated with rh-MDA-7 showed a sig-
nificantly slower rate of migration (electrical resistance
80.1 ± 24.3), when compared with control cells (130 ±
24.3), p = 0.024. Furthermore, the presence of rh-MDA-7
significantly reduced the motility of BC cells. The impact
of rh-MDA-7 on the micro-motion and migration of the
MDA MB-231 cell line is depicted in Figure 2. Exposure
to rh-MDA-7 was only found to exert a marginal effect on
in-vitro growth which did not reach statistical significance.
Immuno-histochemical staining of human breast tis-
sues revealed a substantially greater degree of MDA-7
positivity within normal mammary epithelial cells, com-
pared to virtually no staining in cancer cells, Figure 3A.
Using the NPI as a prognostic indicator, tumours from
patients with poorer prognosis showed significantly
lower MDA-7 transcript levels compared with their
counterparts predicted to have a good prognosis (p =
0.049), Figure 3B. MDA-7 transcript levels were also
found to be correlated with nodal status, with lower
transcript levels found in node positive tumours, Figure
3C. Patients who remained alive and disease free had a
significantly higher levels of MDA-7 compared with
those who developed distant metastasis (3.77 ± 1.32 vs.
0.0019 ± 0.002, p = 0.0058). A significant difference in
MDA-7 expression was identified between tumours
from patients who died of breast cancer and those who
remained disease free after a median follow up of 10
years, with the latter showing higher MDA-7 transcript
levels, p = 0.035. Furthermore, Kaplan-Meier survival
analysis revealed that low levels of MDA-7 were signifi-
cantly correlated with a shorter disease free survival
(mean = 121.7 months, 95% CI = 108.5-134.9) compared
with high levels of expression (mean = 140.4 months,
95% CI = 133.7-147.1), p = 0.0287, Figure 4. The MDA-
7/CK-19 ratio was also found to have significant predic-
tive value for disease free survival (p = 0.0435). Lower
MDA-7 transcript levels were associated with a shorter
overall survival, although this did not reach statistical
significance (p = 0.078 for MDA-7, p = 0.1435 for
MDA-7/CK-19 ratio). ER positive tumours were found
to have lower levels of MDA-7 expression compared
with ER-negative tumours, although this trend did not
reach statistical significance (p = 0.094, NS).
Discussion
The present study adds to the literature in support of
the tumour suppressor function of MDA-7 in solid
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Figure 1 The impact of rh-MDA-7/IL-24 on BC cell migration. Exposure to rh-MDA-7 significantly reduced the wound closure rate of MDA
MB-231 cells, after scratch wounding. Left: control; Right: Cells treated with rh-MDA-7 at 20 ng/ml. Photographs shown are 2 hours after
wounding. Inserts: beginning of the wounding at lower magnification.
Figure 2 Impact of rh-MDA-7 on the micro-motion (A, B) and migration (a, b) of the BC cell line MDA MB-231, using the ECIS model
(1600R for A, B and 9600 for a, b). The presence of rh-MDA-7 significantly reduced the motility of BC cells.
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Figure 3 Localisation of MDA-7 in mammary tissues (A) and levels of MDA-7 transcript in breast cancer tissues in relation to
prognosis (B) and nodal status (C). Breast cancer cells stained virtually negative for MDA-7, in comparison with normal epithelial cells (A-left).
Tumours from patients predicted to have a poorer prognosis and node positive tumours had lower transcript levels (B and C respectively).
Figure 4 MDA-7 expression and Kaplan-Meier survival analysis. Low levels of MDA-7 are significantly correlated with a shorter disease free
survival (mean = 121.7 months, 95% CI = 108.5-134.9) compared with high levels (mean = 140.4 months, 95% CI = 133.7 - 147.1), p = 0.0287.
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human malignancies, with particular reference to BC.
Furthermore, this study is the first to quantitatively eval-
uate MDA-7 mRNA expression in a large cohort of BC
patients and provide correlation with conventional
pathological parameters and clinical outcomes over an
extended follow-up period. MDA-7 expression was
found to be substantially reduced in malignant breast
tissue and low transcript levels were significantly asso-
ciated with unfavourable pathological parameters,
including nodal positivity; and adverse clinical outcomes
including poor prognosis and shorter disease free survi-
val. Despite the inferences drawn, the mechanisms
through which MDA-7 expression exerts its tumour-
specificity, anti-neoplastic activity and efficacy across a
range of human cancers have yet to be fully elucidated
and will undoubtedly be necessary to optimise potential
therapeutic applications.
Several in-vitro studies, including the current study,
have employed rh-MDA-7 for exposure testing in var-
ious experiments, however MDA-7 delivery can also be
achieved via a non-replicating adenovirus, referred to as
adenoviral-mediated gene transfer (Ad-MDA-7) or ade-
noviral-induced expression. Ni et al. [27] have also
investigated the effects of MDA-7 on the growth and
apoptosis of human BC cell lines. In contrast to the
results of the present study which found MDA-7 to
have only a marginal impact on tumour cell growth,
their in-vitro transfection studies demonstrated a clear
dose and time-dependent inhibition of cell growth in
addition to enhanced apoptosis [27]. It is possible that
differences in the method of MDA-7 delivery, in-vitro
assay and cell lines employed could explain some of the
discrepancies in efficacy noted between studies. MDA-7
is believed to be associated with the induction of key
molecules, altering the balance between pro- and anti-
apoptotic proteins which mediate growth inhibition and
apoptosis in several tumour types. Mechanistic studies
undertaken by Sauane et al. [5] have confirmed the spe-
cificity of MDA-7 for transformed cells and demonstrate
localisation to the ER with the induction of sustained
stress as evidenced by expression of ER stress markers.
Apoptosis was found to be mediated through JAK/
STAT independent and p38-mitogen-activated protein
kinase (MAPK)-dependent pathways [5]. In keeping with
this, Sarkar et al. [23] found that Ad-MDA-7 acts in a
tumour-specific manner, resulting in the induction of
various growth arrest and DNA damage inducible
(GADD) genes, via p38-MAPK activation, associated
with the stress response and ER stress pathways [5,23].
Gupta et al. [21] have also shown the importance of
MDA-7 interaction with the ER resident chaperone BiP/
GRP78 for induction of ER stress signals and subsequent
activation of p38-MAPK and GADD gene expression
which culminate in apoptosis. Lebedeva et al. [28] have
demonstrated that these effects are not present in nor-
mal and non-malignant cells. Another interesting obser-
vation with mechanistic implications comes from Suh et
al. [29], who have combined Ad-MDA-7 with a selective
cyclo-oxygenase (COX)-2 inhibitor and identified syner-
gistic in-vitro tumouricidal activity against BC cell lines.
In addition to the aforementioned studies evaluating cell
growth and survival, the present study demonstrated
MDA-7 to have a profound inhibitory effect on the
motility and migration of BC cells in-vitro. It would
appear that MDA-7 has a regulatory role in cell motility
with the ability to modulate and influence the pathways
involved with implications for both local invasion and
metastatic potential.
In-vivo, MDA-7 mediated tumour specific apoptosis
has been demonstrated to be supplemented by an addi-
tional ‘anti-tumour bystander’ effect, with the former
‘intra-cellular killing’ being receptor-independent and
the latter dependent on MDA-7 secretion and canonical
IL-20/IL-22 receptor complexes on the surface of target
cells [14,15,19,22]. In-vivo studies involving the inocula-
tion of nude mice with human BC cell lines have
demonstrated significant growth inhibition following
MDA-7 injection [27]. Sarkar et al. [30] have devised a
dual cancer-specific targeting strategy by constructing a
conditionally replication competent adenovirus which
demonstrates tumour-specific virus replication, in addi-
tion to the expression of MDA-7. Their results are
encouraging, with the complete eradication of both pri-
mary and distant disease in human BC xenografts in
nude mice [30]. MDA-7 has also been shown to influ-
ence endothelial cells, exerting an potentially anti-angio-
genic effect within the tumour vasculature [31]. Chada
et al. [32] found Ad-MDA-7 to mediate p53-indepen-
dent inhibition of tumour growth, cell cycle arrest and
apoptosis, associated with down-regulation of Bcl-2 and
Akt. In-vivo, growth inhibition was demonstrated in
multiple xenograft models. Furthermore, Ad-MDA-7
was demonstrated to have an additive or synergistic
effect in both cellular and animal studies when com-
bined with chemotherapy, biologic therapies and radio-
therapy. These effects were associated with decreased
Bcl-2 expression and BAX up-regulation [32]. Bocangel
et al. [33] evaluated the treatment of a panel of Her-2/
neu over-expressing cell lines and nude mice tumours
with a combination of Ad-MDA-7 gene transfer and
Trastuzumab/Herceptin, the anti-human epidermal
growth factor receptor-2 (Her-2) monoclonal antibody.
The study demonstrated synergistic tumour suppression
with increased cell death, cell cycle block and apoptosis
[33]. Their study is supported by that of McKenzie et al.
[34].
Hence, in addition to utility as a prognostic marker,
MDA-7 appears to offer significant therapeutic potential,
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enticing translational researchers with the prospect of
tumour-specificity and efficacy against a range of solid
human cancers. Indeed, therapeutic potential has been
recently evaluated. The safety and efficacy of Ad-MDA-
7 has been demonstrated in phase-1 clinical trials of
intra-tumoural injection into several solid cancers,
including melanoma [10,11,14,15]. Albeit premature,
MDA-7 has already been referred to by some authors as
the “magic bullet for cancer” and “cancer’s Achilles’
heel” [8,10]. However, further mechanistic studies are
imperative to fully unlock and optimise future therapeu-
tic applications.
Limitations of the present study include the single BC
cell line evaluated and single method of MDA-7 delivery
employed. In addition to motility, migration and growth,
in-vitro studies could be extended to include assays of
adhesion, invasiveness and apoptosis. Immuno-fluores-
cence could also be employed to evaluate changes in
cyto-skeletal arrangement after treatment with rh-MDA-
7. The use of background parenchyma from BC patients
to provide ‘normal tissue’ for comparison is also conten-
tious. Ideally, such material should be derived from
patients without BC in order to avoid any ‘field change’
which may exist within cancer bearing tissues. Although
the sample size and follow-up period were substantial, it
is possible that a larger cohort, particularly with regard
to subgroup analysis, may have influenced several results
which approached, but failed to reach, statistical signifi-
cance. In addition to the measurement of mRNA tran-
script levels, quantitative analysis of protein expression
should be undertaken to ensure concordance. Correla-
tion with associated molecules and other markers of
invasiveness and metastatic competence would also have
been of value.
Conclusion
MDA-7 significantly inhibits the motility and migration
of human BC cells in-vitro. MDA-7 expression is sub-
stantially reduced in malignant breast tissue and low
transcript levels are significantly associated with unfa-
vourable pathological parameters, including nodal posi-
tivity; and adverse clinical outcomes including poor
prognosis and shorter disease free survival. In addition
to its prognostic utility, further mechanistic studies are
warranted to explore the potential for therapeutic
manipulation in human breast cancer.
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